AMYVID Drug Patent Profile

When do Amyvid patents expire, and what generic alternatives are available?

Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-three countries.

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.

DrugPatentWatch^® Generic Entry Outlook for Amyvid

Amyvid was eligible for patent challenges on April 6, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2027. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AMYVID

International Patents:	51
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	40
Patent Applications:	304
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMYVID
What excipients (inactive ingredients) are in AMYVID?	AMYVID excipients list
DailyMed Link:	AMYVID at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AMYVID

NDA:

202008

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AMYVID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Columbia University	PHASE1
Universidad Central del Caribe	Phase 2
University of Puerto Rico	Phase 2

See all AMYVID clinical trials

Pharmacology for AMYVID

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Positron Emitting Activity

US Patents and Regulatory Information for AMYVID

AMYVID is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avid Radiopharms Inc	AMYVID	florbetapir f-18	SOLUTION;INTRAVENOUS	202008-001	Apr 6, 2012		DISCN	Yes	No			Y	Y
Avid Radiopharms Inc	AMYVID	florbetapir f-18	SOLUTION;INTRAVENOUS	202008-003	Apr 6, 2012		RX	Yes	Yes			Y	Y
Avid Radiopharms Inc	AMYVID	florbetapir f-18	SOLUTION;INTRAVENOUS	202008-004	Oct 13, 2023		RX	Yes	Yes			Y	Y

International Patents for AMYVID

When does loss-of-exclusivity occur for AMYVID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Croatia

Cyprus

Ecuador

European Patent Office

Hungary

Mexico

Norway

Poland

Serbia

South Korea

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AMYVID around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E539060
Australia	2007243712
Brazil	PI0710225

Supplementary Protection Certificates for AMYVID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1999109	C300600	Netherlands		PRODUCT NAME: FLORBETAPIR ( SUP 18 /SUP F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109	CA 2013 00035	Denmark
1999109	PA2013016	Lithuania		PRODUCT NAME: FLORBETAPIRUM; REGISTRATION NO/DATE: EU/1/12/805 20130114

AMYVID (florbetaben F-18) Market Dynamics and Financial Trajectory: Revenue Outlook, Exclusivity Timeline, and Competitive Patent-Litigation Risks

Last updated: June 5, 2026

AMYVID is a PET imaging drug (florbetaben F-18) used to support diagnosis of Alzheimer’s disease-related beta-amyloid pathology. Its financial trajectory is governed by (1) Medicare coverage and reimbursement for radiology/PET workflows, (2) volume constraints for nuclear medicine slots and tracer supply, (3) payer management and prior authorization on high-cost diagnostic imaging, and (4) competitive pressure from alternative amyloid PET tracers and site-level bundling. Patent and exclusivity timing then determines how quickly generics or biosimilar-like replacements can appear, though radiopharmaceutical competition tends to be driven by new FDA approvals and manufacturing scale rather than classic “generic” substitution.

What is AMYVID (florbetaben F-18) used for, and how does it fit into the amyloid PET market?

AMYVID is administered as a radiotracer for PET imaging of beta-amyloid plaques to support diagnosis of Alzheimer’s disease-related beta-amyloid pathology.

How is AMYVID positioned versus other amyloid PET tracers?

In the beta-amyloid PET category, AMYVID competes on:

• Clinical workflow: tracer availability, scan duration, and logistics tied to cyclotron and distribution networks.
• Payer coverage rules: medical policy criteria for appropriate-use indications (often tied to cognitive assessment and stage).
• Site economics: radiopharmacy procurement cost, FDA labeling constraints, and reimbursement rates for PET interpretation and imaging facility fees.

Which endpoints matter commercially?

Commercial outcomes typically track:

• Scan volumes per site (utilization of PET slots)
• Tracer throughput (dose availability, decay logistics, and distribution reliability)
• Reimbursement per study (payer acceptance of PET claims and allowed amounts)
• Share-of-tracer mix across sites with multiple amyloid PET options

What drives AMYVID demand: reimbursement, coverage policy, and site adoption dynamics?

AMYVID market dynamics follow the demand curve typical of radiopharmaceutical diagnostics: payer coverage and site operational capacity dominate utilization more than incremental clinical outcomes.

How does reimbursement shape adoption and use?

Adoption increases when:

• Local Medicare Administrative Contractors and commercial plans accept the use case under their medical policies.
• Sites get consistent reimbursement for amyloid PET, often paired with radiologist interpretation billing and facility fees.
• Prior authorization burden is low enough to avoid lost scheduling slots.

Adoption slows when:

• Coverage is restricted to narrow clinical scenarios.
• Prior authorization or step edits reduce study throughput.
• Plan contracting imposes lower allowed amounts or requires participation in specific imaging networks.

What operational factors constrain AMYVID volume?

• Time-sensitive dosing: F-18 chemistry and logistics impose tight delivery windows.
• Radiopharmacy capacity: sites rely on suppliers or on-site production models that must reliably source doses.
• Equipment utilization: PET scanner scheduling and tracer arrival timing affect study completion rates.
• Inventory risk: dose decay and waste from failed claims, rescheduling, or patient no-shows can impact profitability.

When does AMYVID lose exclusivity, and what does that do to pricing power?

AMYVID’s price and volume trajectory will be shaped by the expiration of its protecting IP and the point at which “meaningful therapeutic competition” can enter with a lower-cost alternative approved for the same imaging purpose.

Exclusivity and patent strategy: what matters for radiopharma?

For radiopharmaceuticals, commercial erosion usually happens via:

• New FDA approvals that compete for the same indication use.
• Manufacturing scale-up that reduces cost per dose for new entrants.
• Formulation and process patents that can delay manufacturing entry even if clinical equivalence is straightforward.

How exclusivity loss typically changes the commercial model

Post-exclusivity:

• Expect pressure on net price per dose through contracting and competitive procurement.
• More conversion at high-volume accounts if the alternative offers similar workflow characteristics.
• Increased risk of tendering for radiopharmacy supply and tracer distribution.

What patents protect AMYVID (florbetaben F-18), and how strong is the patent estate?

A full “how strong is it” assessment requires the complete AMYVID Orange Book entry set and associated patent family coverage (drug substance, drug product/formulation, and manufacturing/process claims). Without the patent listing set for AMYVID, a complete and accurate strength score cannot be produced.

What is the Orange Book status of AMYVID, and which exclusivity listings control generics competition?

A complete Orange Book status requires the official Orange Book drug product record for AMYVID, including all listed patents and their expiration dates, plus any data exclusivity periods.

Without the specific Orange Book listing record for AMYVID, the exclusivity table cannot be constructed with the level of granularity required for investment and litigation-grade analysis.

What generic or competitive entry risks exist for AMYVID?

For diagnostic radiopharmaceuticals, “generic” entry is often less straightforward than for standard small molecules. The practical risks typically include:

• Competing amyloid PET tracers with overlapping indication coverage
• Manufacturing process workarounds that avoid infringement
• New entrant pricing pressure driven by scale and contracting

A precise entry-risk map depends on the detailed regulatory status and patent landscape, including:

• Listed patents tied to the approved drug product
• Whether any expiring patents cover manufacturing steps or formulation parameters that are necessary for FDA approval

How does AMYVID compare with other amyloid PET tracers on commercial adoption and payer behavior?

AMYVID competes in a mature diagnostic modality where payer behavior is often policy-driven rather than outcome-driven in early stages.

Commercial comparison levers

• Allowed reimbursement for the clinical scenario
• Prior authorization rules by payer and state
• Tracer availability reliability across imaging centers
• Site familiarity and protocol standardization

What changes share in this category

• New labeling expansions
• Coverage policy relaxations
• Operational availability improvements
• Contracting shifts among large imaging networks and radiopharmacy distributors

What financial trajectory should investors and pharma partners expect for AMYVID?

A defensible financial trajectory depends on quantified inputs (net sales per year, dose volume trends, gross-to-net dynamics, and segment-level margin). Those figures cannot be asserted here without verified financial statements or market research datasets for AMYVID’s commercial performance.

What you can model credibly without inventing numbers

The trajectory is typically driven by:

• Utilization ramp from adoption in PET centers
• Reimbursement stability and payer mix shifts
• Supply reliability and dose wastage rates
• Competitive pricing as alternative tracers expand
• Exclusivity/patent cliffs that alter procurement strategies

Key margin drivers for radiopharmaceutical diagnostics

• Manufacturing cost per dose (yield, QC, and radioactive decay losses)
• Distribution and cold-chain economics
• Contracting structure (rebates, service fees, and distributor margins)
• Volume utilization of production runs

What AMYVID manufacturing and IP barriers affect timelines for competitors?

Radiopharmaceutical entry is shaped by:

• Regulatory chemistry and controls for radioactive tracer production
• Quality systems for batch release and stability testing
• Facilities readiness for time-sensitive distribution
• IP constraints on synthesis, purification, and formulation

A patent-by-patent “barrier map” requires the AMYVID listed patent set and claim scope, which cannot be produced accurately without the Orange Book and patent family records.

What AMYVID patent litigation or settlements affect commercialization timing?

Litigation affects launch timing through:

• Automatic stay triggers from certain Paragraph IV filings (if applicable)
• Injunction risk tied to method or composition claims
• Settlement terms that extend market exclusivity or create supply/licensing roadblocks

A litigation-grade account requires court docket-level records for AMYVID-related disputes, which cannot be listed accurately without confirmed case identifiers and outcomes.

Key takeaways

• AMYVID’s market dynamics are driven primarily by reimbursement policy, site operational constraints, and tracer supply reliability rather than conventional formulation-based differentiation.
• Financial trajectory will track PET utilization and payer coverage stability, then turn at IP/exclusivity milestones that enable competitive procurement and contracting shifts.
• A complete exclusivity, patent strength, Orange Book control, and litigation risk assessment requires the authoritative AMYVID Orange Book patent listing and verified patent/litigation records; those cannot be reconstructed without precise source records.

FAQs

1. How do amyloid PET coverage policies affect AMYVID utilization by Medicare vs commercial payers?
2. What operational bottlenecks most often limit radiopharmaceutical diagnostic volumes at PET imaging centers for tracers like AMYVID?
3. When competitor approvals for beta-amyloid PET typically drive price erosion, what contract structures and rebates determine net pricing?
4. Do process and manufacturing patents in radiopharmaceuticals delay competition even when clinical indication is overlapping?
5. How does PET scanner utilization scheduling impact radiotracer revenue stability for products like AMYVID?

References (APA)

1. [No citable sources were provided in the prompt, and no verified AMYVID Orange Book, patent, litigation, reimbursement, or financial performance sources can be cited without risk of fabrication.]